Roche’s First-Quarter Sales Surge 7%

Swiss pharmaceutical firm Roche announced on Thursday that its sales for the first quarter saw a robust increase of 7%, surpassing forecasts. This growth was primarily fueled by strong performances from its breast cancer treatment, Phesgo, along with its eye medication, Vabysmo, and allergy therapeutic, Xolair.

The group’s total revenue for the quarter reached 15.44 billion Swiss francs ($18.64 billion). This figure modestly exceeded market anticipations, which averaged around 15.4 billion Swiss francs, according to assessments from various market analysts.

Roche previously revealed intentions to allocate $50 billion towards investments within the United States over the upcoming five years.

The company has stated that it still anticipates a high single-digit percentage increase in its adjusted earnings per share for the entire fiscal year.